Medtronic plc's financial statements for the six months ended October 29, 2021, indicate an increase in net sales, operating profit, net income, and earnings per share compared to the same period in 2020. The Consolidated Balance Sheets reveal a decrease in current assets but an increase in total assets and equity. Additionally, the Consolidated Statements of Cash Flows show an increase in net cash provided by operating activities and a decrease in net cash used in investing activities, reflecting the company's financial activities during the period. The text also provides a detailed overview of Medtronic's financial activities, including information on gains and losses on equity and other investments, commercial paper programs, debt obligations, hedging through derivatives, cash flow hedges, net investment hedges, and balance sheet presentation of derivative instruments.
The text provides Management's Discussion and Analysis of Financial Condition and Results of Operations for a medical company, Medtronic plc, and its subsidiaries. It highlights non-GAAP financial measures used to evaluate operational performance and strategic planning and discusses the impact of the COVID-19 pandemic on business operations. The overview includes a summary of revenue, diluted earnings per share, operating cash flow, and net sales by segment and geographic market for the three and six months ended October 29, 2021, with GAAP to Non-GAAP reconciliations reflecting adjustments for various costs and amortization of intangible assets. Furthermore, the text delves into the Neurosciences and Diabetes business segments, detailing product offerings, financial performance, operational costs, sales projections, research and development initiatives, and the impact of COVID-19. It also presents the company's enterprise excellence and simplification programs targeting operational restructuring and efficiency improvements.
The company's operations are exposed to currency exchange rate risk due to global operations, potentially causing fluctuations in earnings and cash flows. The company's currency exchange rate derivative instruments had a gross notional amount of $15.2 billion as of October 29, 2021. A sensitivity analysis showed that a 10% appreciation or depreciation in the U.S. dollar would impact the fair value of these contracts by $1,119 million each. Additionally, the company manages interest rate risk related to their short-term investments and borrowings, with the debt portfolio primarily in U.S. dollars and Euros being fixed rate debt. A sensitivity analysis showed a 10-basis point change in interest rates would impact the fair value of interest rate-sensitive financial instruments by $25 million. For further details on market risk and current market conditions, reference the company's financial statements and management's discussion and analysis.
Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures, concluding they are effective. There have been no significant changes in the internal control over financial reporting during the reviewed period, specifically noting no material impacts related to the COVID-19 pandemic.
The Securities and Exchange Commission updated the threshold for disclosure of legal proceedings under environmental laws involving a governmental party in August 2020, setting it at $1 million. The company believes that matters below this threshold are not material and have detailed their policies in their management's discussion. Legal proceedings and other loss contingencies are further outlined in Note 16 of the consolidated financial statements.
Please provide the text that you would like me to summarize.
During the second quarter of fiscal year 2022, a company repurchased a total of 2,787,099 shares with an average price of $128.62 per share. The repurchases were made as part of a publicly announced program for which a maximum of approximately $4.72 billion worth of shares could still be purchased. In March 2019, the company's Board of Directors authorized the repurchase of $6.0 billion of the company's ordinary shares, with no specific time-frame allocated for these repurchases.
I will summarize the text for you once you provide it in parts. Please go ahead and send the text to me in parts.
I'm unable to summarize the text since no text has been provided yet. Please go ahead and share the text you would like me to summarize.
Medtronic has engaged in activities that require disclosure under the Securities Exchange Act of 1934, authorized by the U.S. Government, involving its Russian affiliate reporting to Russia's Federal Security Service concerning the import of certain medical devices. Although the FSB is on the SDN List, the activities remain authorized by Cyber GL 1B. Following OFAC's designation of FSB pursuant to additional sanctions, Medtronic is required to disclose these dealings as per Section 13(r)(1)(D)(ii), despite OFAC affirming the previous authorizations with the FSB. Medtronic filed required notifications in Russia during the second quarter of fiscal year 2022 per Cyber GL 1B, intending to continue such authorized activities.
The text provided includes a list of exhibits associated with a report or filing. These exhibits consist of certifications by the Chief Executive Officer and Chief Financial Officer under specific sections of the Sarbanes-Oxley Act of 2002, as well as various Inline XBRL documents. The signature section confirms the report's authenticity by the authorized officer of Medtronic plc, Jennifer M. Kirk, on December 2, 2021.
